Trial Profile
Phase II Study of the Combination of MLN 9708 With Lenalidomide as Maintenance Therapy Post Autologous Stem Cell Transplant in Patients With Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2023
Price :
$35
*
At a glance
- Drugs Ixazomib (Primary) ; Lenalidomide (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- 20 Apr 2023 Status changed from active, no longer recruiting to completed.
- 08 Mar 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 08 Mar 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.